Beta-defensin derived cationic antimicrobial peptides with potent killing activity against gram negative and gram positive bacteria

Ming Yang¹, Chunye Zhang¹, Michael Z. Zhang²,³ and Shuping Zhang¹,³*

Abstract

Background: Avian β-defensins (AvBD) are cationic antimicrobial peptides (CAMP) with broad-spectrum antimicrobial activity, chemotactic property, and low host cytotoxicity. However, their bactericidal activity is greatly compromised under physiological salt concentrations which limits the use of these peptides as therapeutic agents. The length and the complex structure involving three conserved disulfide bridges are additional drawbacks associated with high production cost. In the present study, short linear CAMPs (11 to 25 a.a. residues) were developed based on the key functional components of AvBDs with additional modifications. Their biological functions were characterized.

Results: CAMP-t1 contained the CCR2 binding domain (N-terminal loop and adjacent α-helix) of AvBD-12 whereas CAMP-t2 comprised the key a.a. residues responsible for the concentrated positive surface charge and hydrophobicity of AvBD-6. Both CAMP-t1 and CAMP-t2 demonstrated strong antimicrobial activity against Pseudomonas aeruginosa, Staphylococcus aureus and Staphylococcus pseudintermedius. However, CAMP-t1 failed to show chemotactic activity and CAMP-t2, although superior in killing Staphylococcus spp., remained sensitive to salts. Using an integrated design approach, CAMP-t2 was further modified to yield CAMP-A and CAMP-B which possessed the following characteristics: α-helical structure with positively and negatively charged residues aligned on the opposite side of the helix, lack of protease cutting sites, C-terminal poly-Trp tail, N-terminal acetylation, and C-terminal amidation. Both CAMP-A and CAMP-B demonstrated strong antimicrobial activity against multidrug-resistant P. aeruginosa and methicillin-resistant S. pseudintermedius (MRSP) strains. These peptides were resistant to major proteases and fully active at physiological concentrations of NaCl and CaCl₂. The peptides were minimally cytotoxic to avian and murine cells and their therapeutic index was moderate (≥ 4.5).

Conclusions: An integrated design approach can be used to develop short and potent antimicrobial peptides, such as CAMP-A and CAMP-B. The advantageous characteristics, including structural simplicity, resistance to salts and proteases, potent antimicrobial activity, rapid membrane attacking mode, and moderate therapeutic index, suggest that CAMP-A and CAMP-B are excellent candidates for development as therapeutic agents against multidrug-resistant P. aeruginosa and methicillin-resistant staphylococci.

Keywords: Cationic antimicrobial peptides, Peptide design, Salt resistance, Antimicrobial activity, Multidrug-resistant Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus pseudintermedius
Background
The rapid emergence and spread of antimicrobial resistance, particularly those associated with *Pseudomonas aeruginosa* and *Staphylococcus* spp., have become a serious threat to public health [1, 2]. The Centers for Disease Control and Prevention (CDC) estimated that each year in the United States there are approximately 88,000 cases and 11,000 deaths due to infections with methicillin-resistant *Staphylococcus aureus* (MRSA) [3]. Various studies have been conducted to search for new classes of antimicrobial therapeutic agents or antibiotic alternatives with novel targets and modes of action [4]. Host cationic antimicrobial peptides (CAMPs), including linear peptides, α-helical peptides, circular and complex structures with loops and β-sheets constitute the first line of innate defense against microbial pathogens [5]. The features shared by these CAMPs are net positive charge and amphipathicity [6]. The cationic property of CAMP allows for the initial interaction of the peptide with the anionic surface groups of the microbial membrane and the hydrophobicity enables the peptide to integrate into the hydrophobic core of the membrane. The mechanism of action of CAMPs is complex, achieved primarily through membrane damage and possibly subsequent interactions with cellular machineries, and the potential for development of microbial resistance is low [6]. A major group of CAMPs with broad-spectrum antimicrobial activity is β-defensins which contain three cysteine-cysteine disulfide bridges [7]. In addition to their antimicrobial activity and low potential for the development of resistance by bacteria, β-defensins have several other beneficial characteristics, such as modulating host immune response (e.g. chemo-attracting immune cells) [8–11]. Our previous studies show that avian β-defensins (AvBDs) such as AvBD-6 and AvBD-12 possess the following biological properties: broad-spectrum antimicrobial activity, LPS-neutralizing ability, chemotactic activity, and minimal cell cytotoxicity [12–14]. Although β-defensins represent potentially a novel class of antimicrobial therapeutic agents, several obstacles must be overcome, including host cell cytotoxicity, degradation by proteases, loss of antimicrobial activity in the presence of a physiological concentration of salts, and high production cost due to their complex structure [15].

Via the characterization of the structure-function relationship of AvBDs and various analogues, it has been identified that the concentrated surface net positive charge and the N-terminal α-helix and the β2-β3 loop structure are essential functional domains for antimicrobial and chemotactic properties [13]. Linear AvBD analogues with a high net positive charge (+9) and an N-terminal helix-loop possess improved antimicrobial potency and partial chemotactic activity, compared to the wild-type AvBD-12 [16]. However, the linear AvBDs designed in our previous study are still sensitive to physiological salt conditions and the length of the peptides (45 amino acid residues) remain to be shortened to control the manufacturing cost. In addition, a previous study has indicated that linear peptides are more susceptible to protease degradation due to lack of complex tertiary structure stabilized by disulfide bridges found in natural defensin peptides [16].

To increase salt- and protease-resistance, several solutions have been proposed, including: incorporating non-proteinogenic amino acids (e.g. D-amino acid substitutions and bulky amino acid β-naphthylalanin) [17, 18] or LPS binding peptide motif (β-boomerang motif GWKRRKFG) [19], modifying the terminal regions via covalent linkage of a hydrophobic moiety (e.g. a sterol or a fatty acid) [20, 21], peptidomimetic [22], altering the structure, charge, hydrophobicity, and shortening the length of the peptide [23, 24]. These strategies successfully improved the antimicrobial function of CAMPs, but resulted in elevated hemolytic activity and increased manufacturing cost [18, 25]. In the present study, an integrated approach was utilized to design short and compositionally simple CAMPs with potent antimicrobial activity, improved resistance to salts and proteases and minimal cytotoxicity to host cells. The antibacterial property of the newly designed CAMPs against *P. aeruginosa* and *Staphylococcus* spp., including clinical isolates of multidrug-resistant *P. aeruginosa* and methicillin-resistant *S. pseudintermedius* (MRSP) was assessed under various conditions.

Methods

**Bacterial strains and cultures**

*Pseudomonas aeruginosa* (*P. aeruginosa*, ATCC 27853) and *Staphylococcus aureus* (*S. aureus*, ATCC 29213) were used to evaluate the novel CAMPs’ antimicrobial activity, salt- and protease-resistance, and membrane permeability. Ten multiple-drug resistant *P. aeruginosa* and ten methicillin-resistant *S. pseudintermedius* (MRSP) clinical isolates (Table 2) were used to evaluate the antimicrobial efficacy of CAMPs. The clinical isolates were cultured from diagnostic specimens by the microbiology staff at the University of Missouri Veterinary Medical Diagnostic Laboratory as part of standard service. The isolates were donated to the present project with appropriate permission. All bacterial strains were maintained and grown in Luria-Bertani broth or agar (LB, BD Difco™) at 37 °C as described previously [13, 14].

**Peptide synthesis and characteristics**

All peptides were custom synthesized using the standard solid phase 9-fluorenlymethoxy carbonyl (Fmoc) method as previously synthesizing wild-type AvBDs [14] and purified by reverse phase high-performance liquid
chromatography (RP-HPLC) (Lifetein, Hillsborough, NJ). The purity of the synthetic CAMPs was greater than 98.5% as verified by liquid chromatography-mass spectrometry (LC-MS) (Lifetein, Hillsborough, NJ). The charge and hydrophobicity of the newly designed CAMPs at neutral pH were calculated using online Peptide property calculator (PepCalc.com). Protease cutting sites were predicted by using PROSPER (https://prosper.erc.monash.edu.au) and SignalP 4.1 server (http://www.cbs.dtu.dk/services/SignalP/). The three-dimensional structures of AvBDs and the newly designed templates were analyzed by using the I-TASSER (Iterative Threading Assembly Refinement) protein structure and function prediction program (http://zhanglab.ccmb.med.umich.edu/I-TASSER). The distribution of selected amino acid residues was evaluated using PyMOL, a user-sponsored molecular visualization system (https://www.pymol.org/). The helical wheel projection was calculated using the Helical Wheel Projections program (http://rzlab.ucr.edu/scripts/wheel/wheel.cgi).

**Circular dichroism spectrum analysis**
Peptide structures were examined by far-UV circular dichroism (CD) spectroscopy with an Aviv Model 62DS spectrometer (Lakewood, NJ), in the wavelengths ranging from 190 to 250 nm using a path length of 1 nm. The spectra of peptides were measured at a concentration of 0.15 mg/ml in water. Spectra were baseline corrected by subtracting a blank spectrum containing only buffer and expressed as molar ellipticity θ (deg·cm²·mol⁻¹).

**Membrane permeabilizing assay**
The membrane permeabilizing ability was determined using the propidium iodide (PI) uptake assay [26]. PI is a fluorescent molecule that can only penetrate the impaired microbial membrane and intercalate double-stranded DNA. PI staining was done according to the manufacturer’s instruction (Sigma Aldrich). In brief, the mid-logarithmic culture of *P. aeruginosa* (ATCC 27853) was harvested by centrifugation at 9000×g for 10 min and resuspended in PBS (1×10⁸ CFU/ml). The bacteria were treated with each CAMP at a concentration of 1×MIC for 15, 30, 60, and 90 min, respectively. After the addition of PI, the suspension was further incubated for 5 min at room temperature and shielded from light. The bacterial mixture was coated on a microscope slide for analysis of red fluorescence. Images were captured using a Nikon fluorescent microscope with Olympus DP2-BSE software (ECLIPSE E600, Japan) and the number of fluorescent cells per field was count by the ImageJ software (NIH, Bethesda, MD). The assay was performed in triplicate.

**Antimicrobial activity assay**
Minimum inhibitory concentrations (MICs) were determined primarily based on the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [27, 28]. The Muller Hinton (MH) II broth used in MIC assay contained 20–25 mg/L of calcium and 10–12.5 mg/L of magnesium. The procedures were described in previous studies [13, 14]. In brief, two-fold serially diluted CAMPs (2 to 256 μg/ml) were mixed with appropriate bacterial strains at a final concentration of 5×10⁷ CFU/ml in a 96-well microtiter plate (Nunc™, Thermo Fisher Scientific). Following incubation at 37 °C for 24 h, MIC was recorded. All assays were conducted in triplicate.

**Salt resistance assay**
A major hindrance to clinical application of defensin peptides is the interference of function by cationic salts, often referred to as salt sensitivity [29]. The effect of salt on antimicrobial activity of novel CAMPs against *P. aeruginosa* ATCC 27853 and *S. aureus* ATCC 29213 was determined by a colony count assay as described previously [14], in the presence of either 0, 50, 100, and 150 mM NaCl or 0, 0.5, 1, and 2 mM CaCl₂. Two peptide concentrations, 0.5×MIC and 1×MIC, were included. Medium without CAMP served as a negative control. Percent of killing was calculated using the following formula: (CFUcontrol - CFU treated) / CFUcontrol × 100% [14]. All assays were performed in triplicate.

**Hemolytic assay**
The hemolytic assay was performed as described previously [25]. Briefly, mouse red blood cells (RBCs, Innovative Research, Novi, MI) were washed three times with phosphate-buffered saline (PBS, pH 7.4), centrifuged at 1000×g for 10 min, and resuspended in PBS to 10% (v/v). The RBCs were treated with CAMPs at various concentrations ranging from 4 to 512 μg/ml (2-fold serial dilutions) at 37 °C for 1 h. PBS and 0.2% Triton X-100 were used as negative and positive controls, respectively. The supernatant was transferred to a 96-well flat-bottomed polystyrene plate (Thermo Fisher Scientific), and the amount of hemoglobin released into the supernatant was determined by measuring the absorbance with a spectrophotometer at 540 nm. Hemolytic activity was expressed as the percentage of hemolysis and calculated using the following equation: hemolysis (%) = (A_s-A₀)/(A₁₀₀-A₀) × 100, where A_s is the absorbance of the sample, A₁₀₀ is the absorbance of completely lysed RBCs in 0.2% Triton X-100, and A₀ is the absorbance in the complete absence of hemolysis (PBS treatment). The assay was performed in triplicate. The therapeitic index (T.I.) was calculated according to a previously published formula: T.I. = MHC / MICGM [30]. MHC was the minimum hemolytic concentration that caused 5% hemolysis of mouse RBCs. The MICGM was
the minimum inhibitory concentration of the peptide concentrations against bacterial growth after the geometric mean was calculated. MIC$_C$, was the MIC$_{GM}$ for Gram-negative bacteria; MIC$_G$, was the MIC$_{GM}$ for Gram-positive bacteria.

Cell cytotoxicity assay

The cytotoxicity of CAMPs to JAWSII (ATCC CRL-11904) and CHO-K1 (ATCC CCL-61) cells was determined using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, Thermo Fisher Scientific) a cell proliferation assay as described previously [14]. The following peptide concentrations were included in the present study: 64, 128, 256, and 512 μg/ml. Following CAMP treatment, percent of viable cells, relative to the untreated control, was recorded. The assays were performed in triplicate.

Chemotaxis assay

CAMP-induced migration of JAWSII (ATCC CRL-11904) and CHO-K1 (ATCC CCL-61) transfected with CCR-2 was determined using a microchemotaxis assay described previously [14, 31]. Chemotactic indexes (C.I.) was calculated as the number of migrated cells induced by CAMPs divided by the number of migrated cells in the control wells without CAMPs. The assays were repeated five times.

Protease resistance assay

Protease resistance was evaluated by using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by antimicrobial assays. CAMP peptides (10 μg) were treated with various proteases at various concentrations comparable to or higher than that found in host or bacterial culture, including 0.12, 0.6, and 1.2 μg/ml of α-chymotrypsin (Thermo Fisher Scientific) [25], 0.4, 4.4, and 20 μg/ml of matrilysin (metalloproteinase-7, Sigma Aldrich) [32], 0.2, 2, and 20 μg/ml elastase (Thermo Fisher Scientific) [33], or 0.2, 2, and 20 μg/ml of cathepsin B (Thermo Fisher Scientific) [34]. Protease digestion assay was carried out in 20 μl of digestion buffer (25 mM Tris and 150 mM NaCl, pH 7.8) for 1 h at 37 °C. After treatment, the digestion mixture was analyzed by SDS-PAGE on 16.5% polyacrylamide gel. To determine the effect of protease digestion on the antimicrobial activity of two most active CAMPs, each peptide was first treated with a protease for 1 h at 37 °C. The mixture was then diluted to 1 × MIC of the peptide and subjected to colony count assay as described above. Assay buffer containing protease but not peptide and buffer containing untreated peptide were included as controls. Protease inhibition of the antimicrobial activity of CAMP peptide was expressed as a percentage of killing by protease treated peptide in relevance to the untreated peptide. The experiment was repeated three times in triplicate in each assay.

Statistical analysis

Differences between treatment groups were analyzed using the one-way analysis of variance (ANOVA) followed by Duncan’s test for multiple comparisons (SPSS 19.0, IBM Corp., Armonk, NY). Statistical significance was indicated by $p < 0.05$.

Results

Peptide design

Initially, two CAMP templates were designed to retain the antimicrobial and chemotactic properties of wild-type AvBD-6 and AvBD-12, respectively. The first CAMP template (CAMP-t1) possessed the structural domain (N-terminal α-helix and β3–3 loop) of AvBD-12 as well as its analogues A2 and A3 which appeared to be essential to the broad chemotactic activity of AvBD-12 [13]. To increase net positive charge, the negatively charged amino acid residues Asp (D) and Glu (E) were substituted with positively charged amino acid residues Lys (K) or Arg (R). To enhance membrane permeabilization and salt resistance, a poly-Trp tail was incorporated to the C-terminus of the peptide, as it was previously shown that coating antimicrobial peptides with 3 Trp residues significantly increased salt resistance [18, 29, 35]. The resulting peptide CAMP-t1 consisted of 25 amino acid residues: RKFLRRRGE-VAHFSQKSGLYCWVWW. The predicted three-dimensional structure of CAMP-t1 mimics that of AvBD-12 (Fig. 1a). The second CAMP template (CAMP-t2) consisted of the key amino acid residues of AvBD-6: PIHRRIPPRWPRLKRRW, responsible for the concentrated surface charge and hydrophobicity of AvBD-6 [13]. In silico analysis indicated that CAMP-t2 assumed a coil and α-helical structure (Fig. 1b). To optimize antimicrobial activity, CAMP-t2 was subjected to further modifications to create CAMP-A and CAMP-B (Fig. 1c and d) using the following criteria: 1) short in length (≤ 20 a.a. residues), 2) α-helical structure, 3) hydrophobic and hydrophilic residues on opposite sides of the helical surface to facilitate pore formation in bacterial membrane by multiple peptides [36], 4) lack of cutting sites for major proteases: aspartic protease, cysteine protease, metalloprotease, serine proteases, 5) N-terminal acetylation and C-terminal amidation to increase the metabolic stability of CAMPs [37], and 6) addition of C-terminal poly-Trp tail to enhance membrane permeabilization and salt resistance [29, 35].

Structural features

The amino acid sequences and relevant biochemical characteristics of all CAMPs were presented in Table 1. The structures of CAMPs was analyzed by a far-UV spectrometer. In general, the CD spectrum of α-helical structures presents two negative bands at 208 and 222 nm along with a positive band at 192 nm whereas random coil is characterized by a single band below
negative 200 nm [38]. As shown in Fig. 2a, CAMP-t1 showed two weak bands at 202 nm and 225 nm, indicating partial α-helical structure of the peptide. CAMP-t2 displayed a strong single band around 200 nm, confirming the random coil structure as predicted in silico (Fig. 1b). CAMP-A had two negative bands at 200 nm and 225 nm along with a positive band at 190 nm which verified the predicted α-helical structure. CAMP-B showed two weak bands at 202 nm and 225 nm which was consistent with the predicted partial α-helix (Fig. 1d). The CAMPs were subjected to helical wheels projection analysis (Fig. 2b). CAMP-t1 showed random distribution of amino acids and CAMP-t2 showed a large distribution angle of hydrophilic residues (proline and positively charged amino acids) and a small distribution angle of hydrophobic residues. CAMP-A displayed an amphipathic structure with hydrophobic and hydrophilic residues on the opposite site of the helix, which supported the designing feature (Figs. 1c and 2b). CAMP-t1 showed improved antimicrobial activity against Pseudomonas strains and significantly enhanced anti-Staphylococcus activity, compared to CAMP-t2. The MICs of CAMP-t2 against S. aureus and MRSP strains were up to 4-fold lower than that of CAMP-t1 and AvBD-6. CAMP-A, a derivative of CAMP-t2, established further improved antimicrobial

Antimicrobial activity

The minimum inhibitory concentrations of the newly designed CAMPs against P. aeruginosa and S. aureus ATCC reference strains and multidrug-resistant P. aeruginosa and methicillin-resistant S. pseudintermedius (MASP) strains were compared to that of AvBD-6, a natural host CAMP with potent antimicrobial activity under low salt conditions (Table 2). CAMP-t1 showed significantly improved anti-Pseudomonas activity with MIC values 4-fold (for ATCC reference strain) and 2-fold (clinical isolates) lower than that of AvBD-6. CAMP-t1 showed improved antimicrobial activity against S. aureus ATCC reference strain (MIC was 4-fold lower than that of AvBD-6), but not MRSP clinical isolates as evidenced by the high MIC values similar to that of AvBD-6. CAMP-t2, the shorter template, demonstrated similar antimicrobial activity against Pseudomonas strains and significantly enhanced anti-Staphylococcus activity, compared to CAP-t1. The MICs of CAMP-t2 against S. aureus and MRSP strains were up to 4-fold lower than that of CAMP-t1 and AvBD-6. CAMP-A, a derivative of CAMP-t2, established further improved antimicrobial

Table 1 The characteristics of newly designed CAMPs

| Peptide | Amino acid sequence | Length (aa) | Molecular Weight | Charge | Hydrophobicity |
|---------|---------------------|-------------|------------------|--------|----------------|
| CAMP-t1 | RKFLRRGEVAHFSQKSLGLYCW 25 | 3251.84 | + 4 | 44% |
| CAMP-t2 | PIHRRPPRWRLLRRW 17 | 2361.90 | + 7 | 29% |
| CAMP-A  | LRRLKLRPVLRLLRRWW 20 | 2839.55 | + 7 | 50% |
| CAMP-B  | RRWRKRRW 11 | 1869.24 | + 7 | 36% |

*CAMP-t1, CAMP-t2, and CAMP-B are coated with a Trp-tail. N-terminal acetylation and C-terminal amidation were introduced to all peptides.
activity against *P. aeruginosa* and *S. aureus* reference strains, multidrug-resistant *P. aeruginosa* strains and MRSP clinical isolates. The MICs of CAMP-A against *P. aeruginosa* and MRSP isolates were 4- to 32-fold lower than that of AvBD-6. CAMP-B, the second derivative of CAMP-t2, also showed improved antimicrobial activity against *P. aeruginosa* and similar potency against *Staphylococcus* spp. However, CAMP-B was less effective than CAMP-A in killing both *Pseudomonas* spp. and methicillin-resistant *S. pseudintermedius* (*p* < 0.05, Table 2).

**Membrane permeabilizing activity**

A propidium iodide (PI) uptake assay was carried out to determine the membrane permeabilizing activity of newly designed CAMPs (Fig. 3). As shown in Fig. 3a, CAMP-treated *P. aeruginosa* were stained red, indicating that bacterial membranes were damaged by CAMPs. In contrast, untreated bacteria did not show red fluorescence. When the permeabilizing ability was assessed based on the numbers of red cells per field, a time-dependent increase was observed from 15 to 90 min (Fig. 3b and c). However, the number of red bacteria did not increase significantly after 30 min, indicating a fast-action mode of CAMPs. Similar results were obtained for all CAMPs and both bacterial pathogens (Fig. 3).

**Salt resistance**

The impact of cationic salts on the bactericidal activity of CAMPs was assessed using an assay system containing various concentrations of NaCl (0 to 150 mM) or CaCl₂ (0 to 2 mM) at two peptide concentrations (1 × MIC and 0.5 × MIC). As shown in Fig. 4, increasing NaCl and CaCl₂ concentrations had no impact on the bactericidal activity of CAMP-t1 which possesses a C-terminal poly-Trp tail. In contrast, the bactericidal activity of CAMP-B without the Trp tail was negatively affected by increased salt concentrations. At the physiological conditions of NaCl (100 to 150 mM) and CaCl₂ (1 to 2 mM), CAMP-t2 retained approximately 40% of its killing activity against *P. aeruginosa* and *S. aureus*, compared to the results obtained at salt-free condition (Fig. 4). The salt-resistance pattern of CAMP-t2 was similar at two different peptide concentrations. Similar to CAMP-t1, CAMP-A and CAMP-B with a Trp tail exhibited strong tolerance to NaCl and CaCl₂ (Fig. 4).

**Hemolytic activity and cytotoxicity**

The hemolytic activity of CAMPs to mouse RBCs was analyzed (Fig. 5). At high concentrations, CAMP-A lysed approximately 3.6% of mRBCs at 128 μg/ml, 10.1% of
mRBCs at 256 μg/ml, and 17.5% of mRBCs at 512 μg/ml. CAMP-t1, CAMP-t2, and CAMP-B did not cause more than 5% of mRBCs at the concentration of 512 μg/ml. The minimum hemolytic concentration (MHC), geometric means of the MIC (MIC GM), and therapeutic index (T.I.) were determined for each CAMP (Table 3). The average T.I. of CAMP-A and CAMP-B against *P. aeruginosa* were 8.72 ± 2.41 and > 10.90 ± 4.0, respectively. The T.I. of CAMP-A and CAMP-B against *S. aureus* were 6.54 ± 2.01 and > 12.36 ± 4.18, respectively.

The chemotactic activity of the newly designed CAMPs was also determined by MTT cell viability assay (Fig. 6). Exposure of murine immature dendritic cell line JAWSII (Fig. 6a) and CHO-K1 (Fig. 6b) cells to CAMP-t1, CAMP-t2, and CAMP-B at concentrations of 64, 128, 256, and 512 μg/ml for 4 to 48 h did not significantly affect cell viability. However, the viability of both JAWSII and CHO-K1 cells was significantly decreased by treatment with CAMP-A at a concentration equal to or greater than 128 μg/ml. After treatment with CAMP-A, no significant difference in the percentage of cell viability was observed between 4 h treatment and 48 h treatment.

### Chemotactic activity

The chemotactic activity of the CAMPs for JAWSII and CCR2-transfected CHO-K1 cells were determined (Fig. 7). The results indicated that CAMP-t1 with the N-terminal helix-loop structure of AvBD-12 did not show expected chemotactic activity to either cell line (Fig. 7a and b). Interestingly, CAMP-A with the highest antimicrobial activity showed mild chemotactic activity at a concentration of 64 μg/ml (C.I. = 5.13; 77.5% of wild-type AvBD-12, C.I. = 6.62) for JAWSII cells. As shown in Fig. 7c, more JAWSII cell migration was induced by CAMP-A with increasing peptide

| Table 2 | The minimum inhibitory concentration (MIC) of CAMPs |
|---------|---------------------------------------------------|
| Bacteria (strain identification) | CAMP-t1 | CAMP-t2 | CAMP-A | CAMP-B | AvBD-6 |
| *P. aeruginosa* (ATCC 27853) | 64 | 64 | 16 | 32 | > 256 |
| *P. aeruginosa* (1704173) | 128 | 64 | 16 | 32 | > 256 |
| *P. aeruginosa* (1703357) | 128 | 128 | 16 | 64 | > 256 |
| *P. aeruginosa* (1703511) | 128 | 128 | 16 | 64 | > 256 |
| *P. aeruginosa* (1703000) | 128 | 64 | 8 | 32 | > 256 |
| *P. aeruginosa* (1703002) | 128 | 256 | 16 | 64 | > 256 |
| *P. aeruginosa* (1703451) | 128 | 64 | 16 | 64 | > 256 |
| *P. aeruginosa* (1703949) | 128 | 128 | 16 | 64 | > 256 |
| *P. aeruginosa* (1703290) | 128 | 128 | 16 | 64 | > 256 |
| *P. aeruginosa* (1703983) | 128 | 256 | 16 | 64 | > 256 |
| *P. aeruginosa* (1704175) | 128 | 64 | 16 | 32 | > 256 |
| MIC<sub>Average G-</sub> | 122.18 ± 19.29<sup>a</sup> | 122.18 ± 72.71<sup>a</sup> | 15.27 ± 2.41<sup>c</sup> | 52.36 ± 16.14<sup>b</sup> | > 256 |
| *S. aureus* (ATCC 29213) | 64 | 64 | 32 | 32 | 256 |
| *S. pseudintermedius* (13164006)<sup>b</sup> | 256 | 32 | 16 | 32 | > 256 |
| *S. pseudintermedius* (13202008)<sup>b</sup> | 256 | 32 | 16 | 64 | 256 |
| *S. pseudintermedius* (13178007)<sup>b</sup> | 256 | 64 | 16 | 64 | 256 |
| *S. pseudintermedius* (13267017)<sup>b</sup> | 128 | 32 | 16 | 32 | > 256 |
| *S. pseudintermedius* (13252001)<sup>b</sup> | 64 | 32 | 16 | 32 | > 256 |
| *S. pseudintermedius* (13269013)<sup>b</sup> | 256 | 32 | 32 | 32 | > 256 |
| *S. pseudintermedius* (13193006)<sup>b</sup> | 256 | 128 | 32 | 32 | > 256 |
| *S. pseudintermedius* (13228005)<sup>b</sup> | 256 | 32 | 16 | 64 | > 256 |
| *S. pseudintermedius* (13202008)<sup>b</sup> | 256 | 32 | 16 | 64 | > 256 |
| *S. pseudintermedius* (13250111)<sup>b</sup> | 256 | 32 | 32 | 64 | 256 |
| *S. pseudintermedius* (13228005)<sup>b</sup> | 128 | 32 | 16 | 32 | > 256 |
| *S. pseudintermedius* (13207007)<sup>b</sup> | 256 | 32 | 16 | 64 | > 256 |
| *S. pseudintermedius* (13250111)<sup>b</sup> | 256 | 32 | 32 | 64 | 256 |
| MIC<sub>Average G+</sub> | 209.45 ± 81.41<sup>a</sup> | 46.55 ± 29.89<sup>b</sup> | 21.82 ± 8.07<sup>c</sup> | 46.55 ± 16.71<sup>b</sup> | ≥ 256 |

<sup>a</sup>Multidrug resistant clinical isolates of *P. aeruginosa* were resistant to chloramphenicol, tetracycline, sulfamethoxazole, and β-lactam antibiotics: amoxicillin, ampicillin and cefazolin.

<sup>b</sup>Methicillin-resistant *S. pseudintermedius* (MRSP)

Superscripts a, b, and c mean significant difference (p < 0.05) between MICs of four CAMPs against either Gram-negative or Gram-positive bacteria.
concentrations, ranging from 1 to 64 μg/ml. No significant chemotactic activity for CCR-2 transfected CHO-K1 cells was detected (Fig. 7b). CAMP-t2 and CAMP-B did not show any chemotactic activity for either JAWSII or CCR2-CHO-K1 cells.

Protease resistance

The resistance of CAMP-A and CAMP-B, two peptides exhibiting strong antimicrobial activity and salt-resistance, to various proteases was evaluated by subjecting protease-treated peptides to SDS-PAGE (Fig. 8). The results indicated that CAMP-A and CAMP-B were partially digested by α-chymotrypsin at 0.12 to 1.2 μg/ml, as indicated by the presence of peptide bands with lower molecular weight than that of the untreated peptides (Fig. 8a and b). The antimicrobial activity of CAMP-A and CAMP-B against P. aeruginosa decreased significantly post-digestion (Fig. 8c). The digested peptides retained approximately 90% (at 0.12 μg/ml), 80% (at 0.66 μg/ml), and 30% (at 1.2 μg/ml) of the killing activity of the untreated CAMP-A or CAMP-B. In contrast, the anti-Staphylococcus activity was mildly affected only when the CAMPs were treated with the highest concentration (1.2 μg/ml) of α-chymotrypsin (Fig. 8d). CAMP-A and CAMP-B were not cleaved by metalloproteinases matrilysin, elastase, and cathepsin B at concentrations up to 20 μg/ml. Treatment with these proteases did not affect the antimicrobial activity of CAMP-A and CAMP-B (data not shown).

Discussion

Host cationic antimicrobial peptides, such as defensins, have been a subject of research interest because of their broad-spectrum antimicrobial activity and low potential for resistance development. For instance, human α-defensin HD5 and HDP4 showed strong killing activity against S. aureus ATCC 25923 and ATCC 29213 with the lethal doses [39]. Our previous structure-function analysis of AvBDs and their analogues indicates that the highly concentrated surface positive charge plays a predominant role in the antimicrobial potency of the peptides whereas the CCR2-binding domain (N-terminal α-helix along with an adjacent loop) is responsible for the broad-spectrum chemotactic activity for both avian and mammalian dendritic cells [13]. For example, linear AvBD analogues with a high net positive charge (+9), modest hydrophobicity (40%), and a predicted CCR2 binding domain exhibit strong antimicrobial and mild chemotactic activities. However, the linear peptides designed in our previous study are still lengthy (45 amino acid residues) and susceptible to physiological
concentrations of NaCl. Although the sensitivity of AvBD analogues to proteases was not evaluated in our previous studies, investigations conducted by others suggest that linear peptides are susceptible to bacterial metalloprotease, cysteine protease and human neutrophil elastase [38, 39]. To develop antimicrobial peptides suitable for therapeutic or preventive use, we utilized an integrated approach to modify AvBD analogues to achieve the following goals: structurally simple (linear, short and all natural amino acids), resistant to proteases and cationic salts, non-cytotoxic, strong and broad-spectrum antimicrobial activity, and potentially chemotactic for immune cells.

We first designed two CAMP templates, CAMP-t1 and CAMP-t2, by extrapolating the CCR2 binding domain of AvBD-12 (CAMP-t1) and key amino acid

![Fig. 4](image)

**Fig. 4** Effect of salts on the antibacterial activity of CAMPs against *P. aeruginosa* and *S. aureus*. The effect of salts on the antibacterial activity was determined using two peptide concentrations: 1 × MIC and 0.5 × MIC. (a) Percent of killing against *P. aeruginosa* at 0, 50, 100, and 150 mM NaCl; (b) Percent of killing against *S. aureus* at 0, 50, 100, and 150 mM NaCl; (c) Percent of killing against *S. aureus* at 0, 0.5, 1, and 2 mM CaCl₂; (d) Percent of killing against *S. aureus* at 0, 0.5, 1, and 2 mM CaCl₂. Data represent the means ± SD of three independent experiments. An asterisk indicates the statistically significant difference between antimicrobial activity in the presence and absence of salts (*p < 0.05 and **p < 0.01)

![Fig. 5](image)

**Fig. 5** Hemolytic activity of CAMPs. CAMP-induced hemolysis (%) of mouse red blood cells at various peptide concentrations is defined as a percentage of complete hemolysis caused by 0.2% Triton X-100. Data are expressed as the means ± SD of three independent experiments.
residues contributing to the concentrated surface positive charge and hydrophobicity of AvBD-6 (CAMP-t2), respectively. For CAMP-A, the negatively charged amino acid residues (D and E) in AvBD-12 were replaced by positively charged residues (K and R). Because the net positive charge of CAMP-t1 was still relatively low (+4), a poly-Trp tail was incorporated into its C-terminus to boost the antimicrobial activity. Trp is known for its tendency to insert into membrane lipid bilayer and Trp-rich peptides exhibit enhanced antimicrobial activity and salt resistance [18]. N-terminal acetylation and C-terminal amidation (mimicking native proteins) were also incorporated to increase the metabolic stability of peptides as well as their resistance to enzymatic degradation [40]. To evaluate the antimicrobial properties of these peptides, we determined their MICs against *P. aeruginosa* and *Staphylococcus* according to the guidelines of CLSI [27, 28]. Both CAMP-t1 and CAMP-t2 demonstrated improved antimicrobial activity, compared to AvBD-6 and AvBD-12 as well as previously designed AvBD analogues [13, 14]. Although CAMP-t1 retained the N-terminal α-helix and an adjacent loop structure of AvBD-12, it lost the desired chemotactic property [13], suggesting that either the amino acid composition was not optimal or additional structural components were required for CCR2 binding. We then focused on CAMP-t2, a shorter template with a coil-helix structure. This peptide showed stronger

**Table 3** Therapeutic index of new cationic antimicrobial peptides (CAMPs)

| Peptides   | CAMP-t1 | CAMP-t2 | CAMP-A | CAMP-B |
|------------|---------|---------|--------|--------|
| MHC        | > 512   | > 512   | 128    | > 512  |
| MIC\textsubscript{Average} \text{G}⁻ | 122.18 ± 19.29 | 122.18 ± 72.71 | 15.27 ± 2.41 | 52.36 ± 16.14 |
| MIC\textsubscript{Average} \text{G}⁺ | 209.45 ± 81.41 | 46.55 ± 29.89 | 21.82 ± 8.07 | 46.55 ± 16.71 |
| T.I. of G⁻ | > 4.36 ± 1.21 | > 5.45 ± 2.54 | 8.72 ± 2.41 | > 10.90 ± 4.0 |
| T.I. of G⁺ | > 3.27 ± 2.41 | > 13.45 ± 4.48 | 6.54 ± 2.01 | > 12.36 ± 4.18 |

Therapeutic index (T.I.) is defined as the ratio of, MHC to, MIC\textsubscript{G}⁻. MHC (µg/ml) is the minimum hemolytic concentration that caused 5% hemolysis of mouse red blood cells (mRBCs). The MIC\textsubscript{G}⁻ (µg/ml) means the geometric mean (GM) of the, MIC values of the peptides against bacteria. MIC\textsubscript{Average} \text{G}⁻ is the, MIC\textsubscript{G}⁻ for Gram-negative bacteria, MIC\textsubscript{Average} \text{G}⁺ is the MIC\textsubscript{G}⁺ for Gram-positive bacteria.

Fig. 6 Cytotoxicity of CAMPs to JAWSII and CHO-K1 cells. Effect of CAMPs on the viability of mouse immature dendritic JAWSII cells (a) and hamster ovary CHO-K1 cells (b) at 4 and 48 h of incubation with peptide at the concentration of 64 to 512 µg/ml. Results are percentages of viable cells relative to the untreated control cells. The data are expressed as the mean ± SD of three independent experiments. An asterisk indicates a statistically significant difference in the viability of CAMP-treated cells and untreated cells (*p < 0.05 and **p < 0.01).
antimicrobial activity against methicillin-resistant S. pseudintermedius than CAMP-t1 and AvBD-6, but was sensitive to high concentrations of cationic salts. The rest of the study was concentrated primarily on improving the antimicrobial property and salt resistance of CAMP-t2.

Studies have indicated that amphipathicity is a key characteristic required for membrane permeabilization in which hydrophobic residues interact with membrane lipid components while hydrophilic regions either bind with the phospholipid head groups or form the lumen of a membrane pore [5, 14]. Alpha-helical peptides with hydrophobic and hydrophilic residues on opposite sides of the peptide molecule have antimicrobial property [8]. The shorter template, CAMP-t2 with coil-helix structure (only 35% of residues form α-helix), was further modified to form an α-helix structure which confers structural stability [41]. To maximize the antimicrobial activity and minimize the damaging effect on host cell membrane, Trp and Pro residues were incorporated and the amino acid residues were strategically arranged to avoid protease cutting sites predicted using online PROSPER and SignalP 4.1 servers. The resulting peptides, CAMP-A and CAMP-B, demonstrated strong antimicrobial activity against ATCC bacterial reference strains as well as multi-drug resistant P. aeruginosa and methicillin-resistant S. pseudintermedius clinical isolates. With a poly-Trp tail, α-helical structure and increased surface positive charge, CAMP-A and CAMP-B were fully functional at physiological concentrations of NaCl and CaCl2. These peptides were also resistant to metalloproteinases, matrixins and elastase, and cathepsin B at concentrations higher than that in bacterial protein secretion [42] or in mammalian host cells [34]. Although they were still cleaved by α-chymotrypsin, the antimicrobial activity was minimally affected at the concentration of 0.12 μg/ml, about 3 to 40 times higher than the concentration tested in human samples using different methods, 4 ng/ml [43] and 37.5 ng/ml [44]. At a high concentration (1.2 μg/ml), α-chymotrypsin treatment reduced the killing activity against P. aeruginosa (p < 0.05) but not S. aureus (p > 0.05). The discrepancy could be associated with structural difference between Gram-negative and Gram-positive bacterial membranes which warrants further investigation into the mechanism of antimicrobial action of these peptides.

Our previous studies have shown that AvBDs could disrupt bacterial membrane resulting in cell deformation, increased membrane permeabilization, and membrane damage [13, 14]. In the present study, data from propidium iodide (PI) staining assay suggested that the primary mode of action of the newly designed CAMPs...
was membrane attacking, which is considered a mechanism less likely to trigger bacterial resistance. The CAMPs did not show any detectable cytotoxicity and hemolytic activity at the doses required for effective bacterial killing. CAMP-t1, CAMP-t2, and CAMP-B had minimal cytotoxic and hemolytic activities at a relatively high peptide concentration (512 μM/ml). CAMP-A, the most potent antimicrobial peptide, exhibited hemolytic and cytotoxic activities at concentrations equal to or greater than 128 μg/ml which, however, was 6-fold higher than the MIC against *P. aeruginosa* and 4-fold higher than the MIC against *Staphylococcus* spp. The cytotoxic property of CAMP-A was not surprising because the peptide had a relatively high hydrophobicity (50%), which is known hydrophobicity is associated with their cytotoxic effect [45]. The undesired hemolytic activity was still mild compared to other antimicrobial peptides including magainin isolated from the skin of African frog *Xenopus laevis* and melittin from bee venom [46].

It has been suggested that the three conserved disulfide bridges were required for the chemotactic function of β-defensins [14, 47–49]. Data from our previous study indicated that a predicted CCR2 binding domain (N-terminal α-helix and an adjacent β2-β3 loop) in AvBD-12A3 (a linear peptide) without disulfide bridges was chemotactic to JAWSII cells [13]. In the present study, CAMP-t1 with a similar helix-loop domain failed to show chemotactic activity. Interestingly, CAMP-A with high positive charge and modest hydrophobicity induced chemotactic migration of JAWSII cells which occurred possibly via the formyl-peptide receptors like mechanism such reported for human cathelicidin LL-37 [50] and cathelicidin-like pleurocidins [51].

### Conclusion

CAMP-t1 and CAMP-t2 were designed as templates based on key structural and functional components of AvBD-12 and AvBD-6. CAMP-t1 with a predicted CCR binding domain of AvBD-12 demonstrated improved antimicrobial activity but lost the original chemotactic function. CAMP-t2 with key amino acid residues of AvBD-6 showed strong antimicrobial activity, but sensitivity to high concentrations of cationic salts. CAMP-t2 was further modified using an integrated design approach. CAMP-A and CAMP-B possess the following advantageous characteristics: structural simplicity (short and linear), resistance to salts and proteases, potent antimicrobial activity against multidrug-resistant *P. aeruginosa* and methicillin-resistant *Staphylococcus*, rapid membrane attacking mode, and moderate therapeutic index. Our data suggest that CAMP-A and CAMP-B are excellent candidates for development as antimicrobial therapeutic agents.
Abbreviations
ANOVA: One-way analysis of variance; AvBD: Avian beta-defensin; BSA: Bovine serum albumin; CFU: Colony-forming unit; CI: Chemotaxis index; DCs: Dendritic cells; ESI-MS: Electrospray ionization mass spectrometry; FBS: Fetal bovine serum; fMLF: N-Formyl-methionyl-leucyl-phenylalanine; Gnm: 9-Fluorenyl-methoxy-carbonyl; G-CSF: Granulocyte macrophage colony-stimulating factor; HBsAg: Human β-defensin 6; LB: Luria-Bertani; LPS: Lipopolysaccharides; FBS: Fetal bovine serum; fMLF: N-Formyl-methionyl-leucyl-phenylalanine; Gnm: 9-Fluorenyl-methoxy-carbonyl; G-CSF: Granulocyte macrophage colony-stimulating factor; HBsAg: Human β-defensin 6; LB: Luria-Bertani; LPS: Lipopolysaccharides; LT: Lipotocic acid; MIC: Minimum inhibitory concentration; PBS: Phosphate buffered saline; PI: Propidium iodide; RP-HPLC: Reversed-phase high-performance liquid chromatography; SD: Standard deviation

Acknowledgments
The authors would like to thank the bacteriology laboratory of Veterinary Medical Diagnostic Laboratory of University of Missouri for sharing the multi-drug resistant bacterial isolates. The authors thank Dr. Michael T. Herzel for the help with CD spectra analysis. The authors also wish to thank Ms. Christine Yan Zhang for editorial assistance.

Funding
The present study was funded by the College of Veterinary Medicine of the University of Missouri for the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
Conceived and designed the experiments, MY, CZ, MZ, SZ performed the experiments, MY, CZ, MZ, SZ contributed reagents/materials/analysis tools, MY, SZ drafted the manuscript; MY, CZ, MZ, SZ. All authors read and approved the manuscript.

Ethics approval and consent to participate
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA. 2Department of Biomedical Science, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA. 3Veterinary Medical Diagnostic Laboratory, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA.

Received: 26 September 2017 Accepted: 18 May 2018

Published online: 05 June 2018

References
1. Donoghue DJ. Antimicrobial residues in poultry tissues and eggs: human health concerns? Poult Sci. 2003;82(4):618–21.
2. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–83.
3. Mohanram H, Bhattacharjya S. Salt-resistant short antimicrobial peptides. Biopolymers. 2016;106(3):345–56.
4. Straus SK, Hancock REW. Mode of action of the new antibiotic for gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta Biomembr. 2006;1758(9): 1215–23.
5. Jenssen H, Hamil P, Hancock RE. Peptide antimicrobial agents. Curr Microbiol Rev. 2006;19(3):491–511.
6. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003;55(2):127–55.
7. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3(9):710–20.
8. Bahar A, Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6(12):1543.
9. Zhang G, Sunkara LT. Avian antimicrobial host defense peptides: from biology to therapeutic applications. Pharmaceuticals (Basel). 2014;7:220–47.
10. Greber KE, Dawgul M. Antimicrobial peptides under clinical trials. Curr Top Med Chem. 2017;17(5):620–8.
11. Nahlapus M, Håkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194.
12. Zhao L, Yang M, Zhang M, Zhang S. Expression, purification, and in vitro comparative characterization of avian beta-defensin-2, –6, and –12. Avian Dis. 2014;58(4):541–9.
13. Yang M, Zhang C, Zhang MZ, Zhang S. Novel synthetic analogues of avian β-defensin-12: the role of charge, hydrophobicity, and disulfide bridges in biological functions. BMC Microbiol. 2017;17(1):43.
14. Yang M, Zhang C, Zhang X, Zhang MZ, Rottinghaus GE, Zhang S. Structure-function analysis of avian beta-defensin-6 and beta-defensin-12: role of charge and disulfide bridges. BMC Microbiol. 2016;16:210.
15. Mohamed MF, Abdelkhalak A, Seleem MN. Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep. 2016;6:29707.
16. Rozek A, Powers JP, Friedrich CL, Hancock RE. Structure-based design of an indolidecin peptide analogue with increased protease stability. Biochemistry. 2003;42(48):14130–8.
17. Giangaspero A, Sandri L, Tossi A. Amphipathic alpha helical antimicrobial peptides. Eur J Biochem. 2001;268(21):5589–600.
18. Yu HY, Tu CH, Yip BS, Chen HL, Cheng HT, Huang KC, Lo HJ, Cheng JW. Easy strategy to increase salt resistance of antimicrobial peptides. Antimicrob Agents Chemother. 2011;55(10):4918–21.
19. Mohamed H, Bhattacharjya S. Resurrecting inactive antimicrobial peptides from the lipopolysaccharide trap. Antimicrob Agents Chemother. 2014;58(4):1987–96.
20. Jerala R. Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin Investig Drugs. 2007;16(18):1159–69.
21. Chu-Kung AF, Nguyen R, Buzelli KN, Tinell M. Chain length dependence of antimicrobial peptide-fatty acid conjugate activity. J Colloid Interface Sci. 2010;345(2):160–7.
22. Vagner J, Qu H, Hruby VJ. Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol. 2008;12(3):292–6.
23. Ringstad L, Kacprzyk L, Schmidtchen A, Malmsten M. Effects of topology, length, and charge on the activity of a kininogen-derived peptide on lipid membranes and bacteria. Biochim Biophys Acta. 2007;1768(3):715–27.
24. Saravanan R, Li X, Lim K, Mohanram H, Peng L, Mishra B, Basu A, Lee JM, Bhattacharjya S, Leong SS. Design of short membrane selective antimicrobial peptides containing tryptophan and arginine residues for improved activity, salt-resistance, and biocompatibility. Biotechnol Bioeng. 2014;111(1):37–49.
25. Kim H, Jang JH, Kim SC, Cho JH. De novo generation of short antimicrobial peptides with enhanced stability and cell specificity. J Antimicrob Chemother. 2016;71(1):21–32.
26. Tyagi P, Singh M, Kumar H, Kumar A, Mukhopadhyay K. Bacterial activity of curcumin I is associated with damaging of bacterial membrane. PLoS One. 2015;10(3):e0121313.
27. CLSI. M07–A8 methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed; 2009.
28. CLSI. M100–S22 performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. 2012.
29. Chu HL, Yu HY, Yip BS, Chih YH, Liang CW, Cheng HT, Cheng JW. Boosting salt resistance of short antimicrobial peptides. Antimicrob Agents Chemother. 2013;57(8):4050–2.
30. Zhang SK, Song JW, Gong F, Li SB, Chang HY, Xie HM, Gao HW, Tan YX, Ji SP. Design of an α-helical antimicrobial peptide with improved cell-selective and potent anti-biofilm activity. Sci Rep. 2016;6:2794.
31. Falk W, Goodwin RH Jr, Leonard EJ A. 48-well microchemotaxis assay for rapid and accurate measurement of leukocyte migration. J Immunol Methods. 1980;33(3):239–47.
32. Kuhlmann KF, van Till JW, Boermeester MA, de Reuver PR, Tzvetanova ID, Offerhaus GJ, Ten Kate FJ, Busch OR, van Gulik TM, Gouma DJ, Crawford HC. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomark Prev. 2007;16(5):886–91.
33. Forde E, Humphreys H, Greene CM, Fitzgerald-Hughes D, Devocelle M. Potential of host defense peptide produgs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis. Antimicrob Agents Chemother. 2014;58(2):978–85.
34. Doxakis A, Maria A, Savvas P, Zafiroula I. Assessment of the roles of cathepsins B, H and L in the progression of colorectal cancer. Journal Cancer Therapy. 2013;4:1–7.

35. Hansen A, Schafer I, Knuppe D, Seibel P, Hoffmann R. Intracellular toxicity of proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-penetrating peptide penetratin. Antimicrob Agents Chemother. 2012;56(10):5194–201.

36. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–50.

37. Nguyen LT, Chau JK, Perry NA, de Boer L, Zaai SA, Vogel HJ. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One. 2010;5(9):e12684.

38. Gopal R, Park JS, Seo CH, Park Y. Applications of circular dichroism for structural analysis of gelatin and antimicrobial peptides. Int J Mol Sci. 2012;13(3):3229–44.

39. Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human (alpha)-defensins. Antimicrob Agents Chemother. 2005;49(1):269–75.

40. Bulet P, Stocklin R, Menin L. Anti-microbial peptides: from invertebrates to vertebrates. Immunol Rev. 2004;198:169–84.

41. Park IY, Cho JH, Kim KS, Kim YB, Kim MS, Kim SC. Helix stability confers salt resistance upon helical antimicrobial peptides. J Biol Chem. 2004;279(14):13896–901.

42. Shinmar AE, Butler KI, Park HJ. Cathelicidin family of antimicrobial peptides: proteolytic processing and protease resistance. Bioorg Chem. 2003;31(6):425–36.

43. Leifkowitz RB, Schmid-Schonbein GW, Heller MJ. Whole blood assay for elastase, chymotrypsin, matrix metalloproteinase-2, and matrix metalloproteinase-9 activity. Anal Chem. 2010;82(19):8251–8.

44. Iwaki K, Ogawa M, Tanaka S, Kosaki G. Radioimmunoassay for human pancreatic chymotrypsin and measurement of serum immunoreactive chymotrypsin contents in various diseases. Res Commun Chem Pathol Pharmacol. 1983;40(3):489–96.

45. Mora-Navarro C, Míndez-Vega J, Caraballo-León J, Lee M-r, Palecek S, Torres-Lugo M, Ortiz-Bermúdez P. Hydrophobicity of antifungal β-peptides is associated with their cytotoxic effect on in vitro human colon Caco-2 and liver HepG2 cells. PLoS One. 2016;11(3):e0149271.

46. Matsuzaki K, Sugishita K-i, Harada M, Fujii N, Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta Biomembr. 1997;1327(1):119–30.

47. Klüver E, Schulz-Maronde S, Scheid S, Meyer B, Forssmann WG, Adermann K. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry. 2005;44(28):9804–16.

48. Hoover DM, Wu Z, Tucker K, Lu W, Lübkowski J. Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother. 2003;47(9):2804–9.

49. Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinkowski M, Bierer J, Buchner J, Schaller M, Stange EF, Wehkamp J. Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1. Nature. 2011;469(7330):419–23.

50. Tjabringa GS, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol. 2006;140(2):103–12.

51. Pundir P, Catali A, Leggiadro C, Douglas SE, Kulka M. Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation through the FPRL1 receptor. Mucosal Immunol. 2014;7(1):177–87.